StockData
PDS Biotechnology Corp logo

PDS Biotechnology Corp (PDSB) stock

PDSBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$0.78−0.03 (-3.70%)

Close on Nov 20, 2026Market cap $43.51MP/E –Yield –

PDS Biotechnology free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

PDS Biotechnology's free cash flow for the twelve months ending Dec 31, 2025 was -$27.75M. For fiscal 2025 it was -$27.75M. The highest annual figure on record is -$1.57M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$27.75M–
FY2024Dec 31, 2024-$35.06M–
FY2023Dec 31, 2023-$33.64M–
FY2018Dec 31, 2018-$1.57M–
FY2017Dec 31, 2017-$40.89M–
FY2016Dec 31, 2016-$32.88M–
FY2015Dec 31, 2015-$23.06M–
FY2014Dec 31, 2014-$10.60M–
FY2013Dec 31, 2013-$8.18M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$3.70M–
Q3 FY2025Sep 30, 2025-$5.92M–
Q4 FY2024Dec 31, 2024-$8.23M–
Q3 FY2024Sep 30, 2024-$8.00M–
Q4 FY2023Dec 31, 2023-$8.46M–
Q3 FY2023Sep 30, 2023-$7.18M–
Q4 FY2018Dec 31, 2018-$317.63K–
Q3 FY2018Sep 30, 2018-$432.25K–
Q2 FY2018Jun 30, 2018-$415.37K–
Q1 FY2018Mar 31, 2018-$404.34K–
Q4 FY2017Dec 31, 2017-$9.27M–
Q3 FY2017Sep 30, 2017-$11.45M–
Q2 FY2017Jun 30, 2017-$9.30M–
Q1 FY2017Mar 31, 2017-$10.86M–
Q4 FY2016Dec 31, 2016-$6.39M–

More PDS Biotechnology figures

See a number that looks wrong?